Clinical Trials Logo

Delta-9-Tetrahydroncannabinol clinical trials

View clinical trials related to Delta-9-Tetrahydroncannabinol.

Filter by:
  • None
  • Page 1

NCT ID: NCT03206463 Terminated - Bipolar Disorder Clinical Trials

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

THC-BD
Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the acute cognitive and psychophysiological effects of the main psychoactive constituent of cannabis, 9-delta-tetrahydrocannabinol (THC) in individuals with euthymic bipolar disorder (BD), and to begin probing the mechanisms that may underlie its effects in this illness. This study is expected to contribute to a better characterization of specific effects of THC in individuals with BD compared to healthy controls (HC).